Literature DB >> 8823233

Ethnic and genetic determinants of omeprazole disposition and effect.

Y Caraco1, P O Lagerstrom, A J Wood.   

Abstract

OBJECTIVES: To compare the pharmacokinetics and dynamics of omeprazole in white and Chinese subjects.
METHODS: This double-blind two-stage study, performed in the clinical research center of a university hospital, evaluated 15 healthy nonsmoking men (eight white subjects and seven Chinese extensive metabolizers of mephenytoin). Blood samples were obtained over 24 hours after the eighth omeprazole dose (40 mg/day). Omeprazole, omeprazole sulfone, and hydroxyomeprazole pharmacokinetics were calculated from the respective plasma concentration-time curves. Twelve- and 24-hour integrated plasma gastriun (AUCgas12 and AUCgas24) were calculated from the respective plasma gastrin concentrations. A week before the initiation of omeprazole the activities of CYP2D6, CYP2C19, and CYP3A4 were determined by previously established methods.
RESULTS: Omeprazole concentrations were significantly lower (mean area under the plasma concentration time curve extrapolated to infinity [AUCO-infinity] +/- SEM; 7.53 +/- 1.21 versus 12.80 +/- 2.13 mumol.hr.L-1, respectively; p < 0.05) and its oral clearance greater (319 +/- 60 versus 183 +/- 35 ml/min, respectively; p < 0.05) in the white subjects than in the Chinese subjects. Omeprazole and omeprazole sulfone AUCO-infinity values were well correlated with the S/R mephenytoin ratio (r = 0.82 and r = 0.84, respectively; p < 0.001) and with urinary 4'-hydroxymephenytoin (r = -0.58 [p < 0.03] and r = -0.52 [p < 0.02], respectively). Fasting gastrin, AUCgas12, and AUCgas24 were significantly greater in the Chinese subjects than in the white subjects (30.0 +/- 6.4 versus 14.4 +/- 1.2 pmol, respectively [p < 0.02]; 661 +/- 114 versus 334 +/- 38 pmol.hr.L-1, respectively [p < 0.002]; and 1414 +/- 228 versus 747 +/- 99 pmol.hr.L-1, respectively [p < 0.004]). In addition, the S/R mephenytoin ratio and omeprazole AUCO-infinity correlated with the extent of omeprazole induced hypergastrinemia.
CONCLUSION: The metabolism of omeprazole and the rise in gastrin concentration after its administration is genetically determined and ethnically dependent.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8823233     DOI: 10.1016/S0009-9236(96)90131-9

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

Review 1.  Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.

Authors:  Mei-Ling Chen
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Some Observations on PPI Therapy for Bleeding Ulcer.

Authors:  Grigoris I Leontiadis; Colin W Howden
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-08

Review 3.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

4.  A randomized controlled trial comparing two different dosages of infusional pantoprazole in peptic ulcer bleeding.

Authors:  Yao-Chun Hsu; Chin-Lin Perng; Tzeng-Huey Yang; Chaur-Shine Wang; Wei-Lun Hsu; Huei-Tang Wu; Yang-Chih Cheng; Ming-Feng Chiang; Hwai-Jeng Lin
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

5.  Possible interethnic differences in omeprazole pharmacokinetics : comparison of Jordanian Arabs with other populations.

Authors:  Sireen Shilbayeh; Maha F Tutunji
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.

Authors:  Yukio Ishizawa; Norio Yasui-Furukori; Takenori Takahata; Mutsuo Sasaki; Tomonori Tateishi
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.

Authors:  K Dilger; Z Zheng; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 8.  Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding.

Authors:  Jun Wang; Kehu Yang; Bin Ma; Jinhui Tian; Yali Liu; Zhenggang Bai; Lei Jiang; Shaoliang Sun; Jun Li; Ruifeng Liu; Xiangyong Hao; Xiaodong He
Journal:  Can J Gastroenterol       Date:  2009-04       Impact factor: 3.522

9.  A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers.

Authors:  Monika Schöller-Gyüre; Thomas N Kakuda; Goedele De Smedt; Hilde Vanaken; Marie-Paule Bouche; Monika Peeters; Brian Woodfall; Richard M W Hoetelmans
Journal:  Br J Clin Pharmacol       Date:  2008-04-25       Impact factor: 4.335

Review 10.  The short-term medical management of non-variceal upper gastrointestinal bleeding.

Authors:  Thomas O G Kovacs; Dennis M Jensen
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.